Posters

    Untargeted Metabolomics Application to Monitor Urine Samples by Ultra-High-Pressure Liquid Chromatography Coupled to High-Resolution Mass Spectrometry

    Laszlo, C.; Haiduc, A.; Fatarova, M.; Dossin, E.; de Jong, F.; Beecher, C.; Kamleh, A.; Guy, P. A.; Ivanov, N. V.; Peitsch, M.
    Conference date
    Jun 24, 2019
    Conference name

    Metabolomics 2019
    Link to more information
    Topic
    Summary

    In order to meet the demands of high-throughput metabolomics analysis, we established urine sample preparation method on 96-well plates and an efficient liquid chromatography (LC) coupled to high-resolution mass spectrometry (MS) method using the latest model of the Vanquish™ Tandem LC system. The separation of urine metabolites was performed using two Hypersil GOLD™ C18 columns (150 x 2.1 mm, 1.9 µm) operating in parallel and running with a fast linear gradient of acetonitrile containing 0.1% formic acid, ramping from 5% to 95% in 10 minutes, alternating between the two columns. Dual-column operation with column reconditioning maintains full occupancy of the MS instrument (MS acquisition of column A during re-equilibration of column B). MS detection was realized on a Q Exactive™ HF mass spectrometer operating in positive and negative electrospray ionization acquisition modes. Data quality consistency was assessed through various pooled urine quality control samples injected on both columns processed by principal component analysis. To prevent possible drift in retention time across the columns, various reference index markers eluting across the gradient were analyzed at the beginning and the end of the 96-well plate series on each column. Retention index values were calculated to provide reproducible results over time. In addition, we have assessed the 13C yeast extract (TruQuant IQQ Workflow Kit, IROA®) to obtain a more robust method for metabolite identification and quantification. 

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.